

Distribution Agreement

In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.

Signature:

Richard A. Powers

Date

Associations between Metabolites and Obesity:
A Cross-Sectional Study in South African Adults with HIV

By

Richard A. Powers
Master of Public Health

Global Epidemiology

Dr. Yan Sun
Committee Chair

Dr. Vincent Marconi
Committee Member

Associations between Metabolites and Obesity:
A Cross-Sectional Study in South African Adults with HIV

By

Richard A. Powers

B.A.
Georgia State University
2019

Thesis Committee Chair: Dr. Yan Sun, Ph.D., M.S.

An abstract of
A thesis submitted to the Faculty of the
Rollins School of Public Health of Emory University
in partial fulfillment of the requirements for the degree of
Master of Public Health
in Global Epidemiology
2023

Abstract

Associations between Metabolites and Obesity:
A Cross-Sectional Study in South African Adults with HIV
By Richard A. Powers

Background: HIV infection puts individuals at increased risk for obesity and related chronic illnesses, and the link between specific metabolites and body mass index within this population, especially among those of African ancestry, is not well-defined. By using validated metabolites, this study aims to identify potential associations with BMI and develop targeted interventions to address health disparities in underrepresented populations.

Methods: This study conducted a cross-sectional study of 340 participants to investigate the association between metabolites and BMI. Linear regression was used to test the associations between validated metabolites and BMI while controlling for age, sex, race/ethnicity, and smoking status.

Results: Among the 154 validated metabolites, there were 20 with significant associations with BMI. 1-naphthylamine and tryptophan had the most statistically significant associations (p -value < 0.001), and phenylalanine, a replicated metabolite identified in prior studies, was also found to be highly significant (p -value = 0.004).

Discussion: The association between tryptophan and phenylalanine with BMI and obesity-related diseases may have significant public health implications as obesity is a major risk factor for a range of chronic illnesses. Future studies need to consider social determinants of health, such as food insecurity and SES, in addressing obesity-related health disparities. Further research is required to establish a concrete relationship and determine the precise association and validity of these metabolites with obesity-related outcomes.

Associations between Metabolites and Obesity:
A Cross-Sectional Study in South African Adults with HIV

By

Richard A. Powers

B.A.
Georgia State University
2019

Thesis Committee Chair: Dr. Yan Sun, Ph.D., M.S.

A thesis submitted to the Faculty of the
Rollins School of Public Health of Emory University
in partial fulfillment of the requirements for the degree of
Master of Public Health
in Global Epidemiology
2023

INTRODUCTION

Over the last 40 years, advances in antiretroviral therapy (ART) have greatly increased the longevity and quality of life for people with HIV (PWH). However, along with these great advances arose a new set of challenges to overcome. Age-related diseases, such as type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and cancer, pose a much greater risk to PWH now than in the past (1,2). This trend is especially pronounced in many low- and middle-income countries (LMICs), causing an added strain to existing HIV care around the globe.

Obesity is a major risk factor for adverse health outcomes, such as T2D and CVD, and places a significant financial burden on the public health infrastructure in South Africa (3–5). The relationship between obesity and these chronic illnesses is exacerbated among PWH (1,2,6,7). According to the World Health Organization (WHO), over 1 billion people worldwide are considered obese, and this number is expected to increase in the coming years (4). South Africa has among the highest prevalence of obesity in sub-Saharan Africa, with 68% of women and 31% of men considered either overweight or obese (3,8). South Africa also has one of the highest prevalence of HIV infection in the world, with the province of KwaZulu-Natal (KZN) bearing the greatest burden (9). The findings of this study, which explores the associations between metabolites and obesity in PWH on ART, can help identify metabolic pathways and inform the development of targeted interventions to promote healthier lives for PWH. By identifying specific metabolites that are associated with obesity in this population, the analysis may contribute valuable evidence towards implementing targeted interventions that may prevent or treat obesity in PWH, ultimately leading to improved health outcomes and quality of life for this vulnerable population.

BACKGROUND

Metabolome-wide association studies (MWAS) are used to identify potential associations between metabolic variables and disease outcomes (10). This approach utilizes metabolic profiling via spectroscopic techniques (e.g., nuclear magnetic resonance spectroscopy and mass spectrometry) to measure thousands of metabolites within the body. Metabolites are small molecules that are produced as a result of various metabolic processes in the body (11). They can serve as indicators of biological functions and can provide insights into disease pathogenesis.

Several studies have utilized metabolomics to investigate the metabolic changes associated with obesity and to identify potential biomarkers for obesity-related diseases. Early MWAS research utilized an untargeted metabolomic approach to investigate metabolite changes and their possible association with obesity (12,13) This approach uses a top-down strategy, and its primary objective is hypothesis-generating (13). Technical advances in metabolomics led to more targeted approaches, which used identified and validated metabolites based on prior research. Some early studies using this strategy revealed specific metabolites associated with body fat distribution and risk factors for developing adiposity-associated co-morbidities in the general adult population, regardless of obesity status (14–17). In more recent studies, researchers have investigated the differences in metabolomic profiles of obese and normal-weight adults with obesity-related diseases (18–21). The top associated metabolites and metabolic pathways reported in the studies referenced above are presented in Table 1.

The identification of metabolites associated with body mass index (BMI) in PWH may help in the early detection of individuals at risk of becoming overweight or obese, which can lead to higher risk for developing non-communicable diseases (NCDs), and enable targeted interventions to prevent further weight gain (10). MWAS and similar research frameworks have

Table 1: Top associated metabolites and metabolic pathways from previous literature

| Authors | Year | Metabolite/Metabolic Pathways |
|-------------------|-------------|---|
| Hanhineva et al. | 2013 | Insulin, Cholesterol, VLDL, TG 54:1-3, TG 50:1-5, TG 55:1, PC 32:0 |
| Kim et al. | 2013 | Betaine, Benzoic acid, Pyroglutamic acid, Pipecolic acid, N-phenylacetamide, Uric acid, L-aspartyl-L-phenylalanine, LysoPCs (C18:1, C18:2, C20:1, and C20:4), L-proline, Valine, L-leucine/isoleucine, Hypoxanthine, Glutamine, L-methionine, Phenylpyruvic acid, Carnitine derivatives, LysoPCs (C14:0, PC16:0, C15:0, C16:0, C17:1, C18:0, and C22:0) |
| Chen et al. | 2015 | L-kynurenine, Glycerophosphocholine (GPC), Glycerol 1-phosphate, Glycolic acid, Tagatose, Methyl palmitate, and Uric acid |
| Wang et al. | 2016 | 2-Octenoylcarnitine, Eicosadienoic acid, 12-hydroperoxyeicosatetraenoic acid, 4-hydroxyestrone sulfate, LysoPE[18:1(11Z)/0:0], Thromboxane B2, Pyridinoline, Vitamin D3 glucosiduronate, 9,10-DHOME |
| Chashmniam et al. | 2020 | Glutamine, Asparagine, Alanine, L-Glutathione Reduced, 2-Aminobutyrate, Taurine, Betaine, Choline, D-Sphingosine, Glycine, Histidine, Isoleucine, L-Proline, Cholic Acid, Carnitine |

Note: Only studies that explicitly reported the identified metabolites in their results were included above and, therefore, not all referenced studies are represented.

been primarily conducted in populations of European ancestry and from high-income countries. However, there is a need to validate these critical findings in populations of non-European ancestry and in LMICs (22).

Recently, Liu et al. (2022) performed a genome-wide association study (mGWAS) of multiple metabolites using a sample from a large cohort of PWH residing in South Africa. A major emphasis of the analysis was to sample individuals from diverse ancestries and geographic regions in order to assess gene-metabolite associations and identify associations across diverse populations; this could provide insights into disease risk at the molecular level and reduce health disparities among underrepresented populations (22). The mGWAS of 154 metabolites identified 22 significant genetic associations, at $p < 5 \times 10^{-8}$, and replicated several genetic associations of

metabolites in the general population. By analyzing the same population, our study utilizes the 154 metabolites previously identified to build more robust evidence of potential associations between these validated metabolites and BMI.

Our study uses BMI as an approximation for adiposity, providing a means of creating defined categories to determine weight status within the sample. Obesity has been identified as a significant risk factor for various chronic illnesses and metabolic dysfunction including T2D, CVD, and other NCDs (4,5). Huang et al. (2022) conducted a phenome-wide association study (PheWAS) of BMI and various adverse health outcomes (5). The investigators found BMI to be implicated as a genetically associated risk factor for CVD, chronic renal failure, respiratory failure, and musculoskeletal disorders among other disease outcomes. These chronic NCDs greatly increase disability-adjusted life years (DALYs) both globally and in South Africa (23). Between 2002 and 2016, the prevalence of overweight and obese women increased from 56% to 68% and rose similarly from 29% to 31% among men in South Africa (3,8). The province of KZN, where the study was conducted, has the highest rate of severe obesity among men and the second highest rate among women (8).

HIV/AIDS is the top contributor to both the national mortality rate and DALYs per 100,000 in South Africa (24). In 2012, the prevalence of HIV in South Africa was 12%, and by 2017, this number rose to 14% (or ~8 million people) despite increased funding and prevention efforts. The HIV incidence rate was 320,000 new infections per year between 2012 and 2017 (25). The highest prevalence of HIV in South Africa is in KZN with 18% of the population living with the illness (9). Together, obesity and HIV significantly predispose PWH for developing NCDs and living lower quality, shortened lifespans.

To date, few studies have investigated the relationship between metabolites and BMI among PWH and in LMICs such as South Africa (22). Furthermore, as has been emphasized, most related studies have performed these tests using samples from populations of mostly European ancestry (5,22,26–30). This study aims to address this gap in knowledge and provide valuable insights into the molecular mechanisms that underlie the association between obesity and related adverse health outcomes in PWH. Specific aims included (1) identifying key associations between BMI and validated metabolites, and (2) performing an ad hoc mediation analysis to identify potential mediators or effect modifiers (e.g., SES) between metabolites and BMI. The overarching goal of this study is to elucidate the complex relationship between obesity and chronic complications observed among PWH. The results of this research may assist in designing targeted interventions that promote healthier lifestyles for PWH. By pinpointing the particular metabolites linked to obesity in this group, the investigation can provide significant evidence for creating interventions that may avert or treat obesity in PWH. Ultimately, this could enhance the health outcomes and overall quality of life for this vulnerable population.

METHODS

Study Design and Participants

This study was a cross-sectional analysis of data from a sub-cohort of the KZN HIV/AIDS Drug Resistance Surveillance Study (ADReSS) conducted within several clinics in KZN, South Africa. The study sample included 500 participants recruited from a state-funded hospital clinic, RK Khan (RKK), located in a peri-urban township, Chatsworth, near Durban, KZN from 2014 to 2016. The study included participants who were aged 18 years or older, qualified for

ART, and provided written informed consent. A total of 340 of these participants with metabolomics data available were included in the analysis.

Data Collection

Data were collected through questionnaires, physical examinations, and laboratory tests. The study collected demographic information, including age, sex, and race/ethnicity, as well as estimates of socioeconomic status, smoking status, and transportation methods used to attend clinic visits. Additionally, metabolic data were collected at baseline through laboratory testing. Ethics approval was obtained prior to the start of the study and approved by the institutional review boards at University of KwaZulu-Natal and Emory University.

Data Cleaning and Variable Imputation

All data cleaning was performed using R version 4.2.2. The following packages were used for data manipulation and analysis: tidyverse, rio, janitor, skimr, naniar, gtsummary, rstatix, sjPlot, mlbench, table1, nlme, ggplot2, qqman, flextable, knitr, and car. Data cleaning included merging datasets and removing duplicate entries.

Metabolomic data were quantified using high-resolution metabolic profiling with liquid chromatography and mass spectrometry to analyze plasma samples from participants prior to ART initiation. The metabolites were extracted using apLCMS and xMSanalyzer, and annotated using an in-house library. A total of 154 metabolites were successfully matched, with annotations allowing for small variations in mass and retention time. For a more detailed and comprehensive description of the metabolomic profiling process, refer to Liu et al., 2022. BMI was calculated using height and weight data collected closest to the blood draw used to calculate the

metabolomic data. BMI Status was categorized using CDC standard weight status categories (31). BMI has been criticized for its use to approximate adiposity; however, given the inability to gather relevant data using dual-energy x-ray absorptiometry (DXA), the gold standard, BMI has been found to be a suitable proxy variable among both general populations and PWH residing in East Africa (27,32). Covariates included in the model were age, sex, race, smoking status, and wealth indices. Age, sex, race, and smoking status were controlled for in the initial model. The decision to control for these variables was based on *a priori* evidence derived from similar studies (22,33–35).

Statistical Analysis

Data analyses were conducted using descriptive statistics and statistical tests, as appropriate. Linear regression was used to test the univariate associations of each validated metabolite as a predictor for BMI, controlling for race/ethnicity, sex, age, and smoking status. For this test, statistical significance was determined using $p < 0.05$. All analyses were conducted using R version 4.2.2 (URL Available online: <https://www.R-project.org/>). Summary tables were created using the gtsummary, table1, and flextable packages. Figures were created using the ggplot2 and qqman packages.

RESULTS

Characteristics of Study Participants

The cohort was comprised of 340 participants, all residing in South Africa and receiving care at the ART clinic at RKK Hospital in Chatsworth, KZN, South Africa. Among the study population, 59% of participants were female. The cohort had a median age at enrollment of 33

(± 10) years with age staying relatively consistent across BMI status groups. The sample overwhelmingly self-identified as Black. The median BMI was 23 (± 6.0) kg/m². For the overall cohort, 42% were considered either overweight or obese. Male participants had a lower median BMI compared to female participants in the study [21 (± 5.0) vs. 25 (± 6.3)] as well as had a lower percent who were considered overweight or obese. These statistics are consistent with the trends observed in the latest national statistics (4,8). Lastly, the majority of participants (58%) reported having less than a high school education. These data are presented in Table 2.

Collinearity was assessed among the significant metabolites by calculating variance inflation factor (VIF) values for each variable within each model. No variable had a VIF value greater than 5, indicating that collinearity is unlikely to be a concern among these variables.

Of the 154 targeted metabolites, the model yielded 20 metabolites associated with BMI with nominal p-values less than 0.05, after controlling for race/ethnicity, sex, age, and smoking status. These results, along with the metabolic feature, beta, standard error (SE), p-values, and false discovery rate (FDR) q-values are presented in Table 3, sorted by p-value.

Omics studies involve the analysis of a large number of variables, which increases the likelihood of obtaining false positive results; to address this issue, multiple testing correction methods are commonly employed (10,36). In this study, we used the FDR method as the correction approach. FDR controls for the expected proportion of false positive results among all tests deemed significant. This method is preferred over other statistical approaches, such as the Bonferroni correction, because it has greater power to detect significant results and is less likely to produce false negatives (36). By using FDR correction, we aimed to minimize the risk of reporting false positive findings and to increase the reliability of our results. All metabolites with a statistically significant p-value also had q-values less than 0.05 making them significant even

Table 2: Demographics and Summary Statistics

| | Total (N=340) | Under- weight (N=30, 9%) | Normal Weight (N=168, 49%) | Over- weight (N=78, 23%) | Obese (N=64, 19%) |
|-------------------------------------|--------------------------|---|---|---|------------------------------|
| Sex | | | | | |
| Male | 141 (41%) | 19 (63%) | 82 (49%) | 27 (35%) | 13 (20%) |
| Female | 199 (59%) | 11 (37%) | 86 (51%) | 51 (65%) | 51 (80%) |
| Age at Enrollment, years | | | | | |
| Median (SD) | 33 (± 10) | 34 (± 10) | 30 (± 10) | 35 (± 9.3) | 34 (± 10) |
| Race/Ethnicity | | | | | |
| Black | 322 (95%) | 27 (90%) | 162 (96%) | 73 (94%) | 60 (94%) |
| Colored | 3 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 2 (3%) |
| Indian | 15 (4%) | 3 (10%) | 5 (3%) | 5 (6%) | 2 (3%) |
| BMI, kg/m² | | | | | |
| Median (SD) | 23 (± 6.0) | 18 (± 1.3) | 21 (± 1.7) | 27 (± 1.5) | 34 (± 4.6) |
| Smoking Status | | | | | |
| Smokes | 21 (6%) | 2 (7%) | 15 (9%) | 3 (4%) | 1 (2%) |
| Does Not Smoke | 319 (94%) | 28 (93%) | 153 (91%) | 75 (96%) | 63 (98%) |
| Education Level | | | | | |
| No Education | 13 (4%) | 1 (3%) | 6 (4%) | 5 (6%) | 1 (2%) |
| Less than High School | 196 (58%) | 22 (73%) | 97 (58%) | 37 (47%) | 40 (62%) |
| High School or Equivalent | 52 (15%) | 2 (7%) | 26 (15%) | 16 (21%) | 8 (12%) |
| Certificate or Diploma | 63 (19%) | 5 (17%) | 31 (18%) | 14 (18%) | 13 (20%) |
| College Degree | 16 (5%) | 0 (0%) | 8 (5%) | 6 (8%) | 2 (3%) |

Note: Percentages may not sum to 100% due to rounding.

after the multiple testing correction.

A quantile-quantile (QQ) plot was created to compare the distribution of observed p-values from the analysis to the expected $\log_{10}(\text{p-values})$ under the null hypothesis. Based on

Figure 1, the observed p-values appear to be mostly smaller than expected under the null hypothesis.

A volcano plot, presented in Figure 2, is another type of graphical tool commonly used in omics studies to display the results of a statistical test comparing two groups (37). It plots the negative logarithm of the p-value on the y-axis and the log₂-fold change on the x-axis, with each data point representing one of the 154 metabolites tested. The plot helps to visualize which metabolites are significantly differentially expressed between two groups and provides insight into both the magnitude and direction of changes.

Figure 1: Quantile-quantile (QQ) Plot of p-values




Figure 2: Volcano Plot




Table 3: Metabolites associated with body mass index.

| Metabolite Name | Metabolic Feature | Beta | SE | P-value | Q-value |
|--------------------------|-------------------|-------|------|---------|---------|
| 1-NAPHTHYLAMINE | mz144.0807_t46.2 | 1.43 | 0.39 | < 0.001 | 0.005 |
| TRYPTOPHAN | mz205.0972_t45.9 | 1.36 | 0.38 | < 0.001 | 0.005 |
| PHENYLALANINE | mz166.0862_t46.5 | 1.08 | 0.36 | 0.004 | 0.023 |
| HOMOCYSTEINE | mz136.0428_t56.3 | -0.98 | 0.36 | 0.008 | 0.038 |
| URIDINE | mz245.0769_t45.3 | -0.83 | 0.34 | 0.015 | 0.047 |
| CYSTINE | mz239.017_t24.2 | 0.84 | 0.35 | 0.016 | 0.047 |
| NORLEUCINE | mz130.0873_t23 | 0.94 | 0.39 | 0.017 | 0.047 |
| CREATINE | mz132.0765_t72.5 | 0.84 | 0.37 | 0.023 | 0.049 |
| BETA-ALANINE | mz90.0551_t71.3 | 0.82 | 0.37 | 0.026 | 0.049 |
| 3-METHYL-2-OXINDOLE | mz162.056_t60.4 | 0.81 | 0.38 | 0.032 | 0.049 |
| SERINE | mz104.0351_t26.8 | 0.79 | 0.38 | 0.038 | 0.049 |
| N-ACETYL-D-TRYPTOPHAN | mz247.1076_t34.1 | -0.76 | 0.36 | 0.038 | 0.049 |
| CITRULLINE | mz176.1029_t90.6 | -0.74 | 0.36 | 0.041 | 0.049 |
| 3-HYDROXYBENZYL ALCOHOL | mz123.045_t27.4 | -0.76 | 0.37 | 0.042 | 0.049 |
| CITRAMALATE | mz147.0298_t23.1 | -0.82 | 0.41 | 0.046 | 0.049 |
| N-AMIDINO-L-ASPARTATE | mz176.0663_t49 | 0.74 | 0.37 | 0.046 | 0.049 |
| CAFFEATE | mz179.035_t25.5 | -0.70 | 0.35 | 0.047 | 0.049 |
| D-PANTOTHENIC ACID | mz220.1182_t64.5 | 0.74 | 0.37 | 0.048 | 0.049 |
| URACIL | mz113.0347_t39.3 | -0.72 | 0.36 | 0.049 | 0.049 |
| N-ACETYL-L-PHENYLALANINE | mz206.0825_t46.2 | 0.72 | 0.36 | 0.049 | 0.049 |

DISCUSSION

South Africa, similar to many other LMICs, faces significant public health challenges due to a high prevalence of infectious diseases and a growing burden of NCDs. Most studies investigating the relationships between metabolomics and adverse health outcomes have been conducted among populations of European ancestry and from high-income countries. These studies may not be relevant for individuals of non-European ancestry living in LMICs, as they may have different genetic ancestries and environmental exposures (22).

Metabolites of Interest

The association study between the 154 metabolites and BMI yielded 20 significant results (Table 3). 1-naphthylamine and tryptophan were the most statistically significant, and phenylalanine was a replicated BMI association, based on previous literature, with a high statistical significance.

1-naphthylamine is not a natural occurring metabolite but has a role as a human xenobiotic metabolite (38), and it was found to be highly significant in the analysis (p -value < 0.001). There was very little existing literature on the association of this metabolite with BMI or obesity. One study, involving animal models, found 1-naphthylamine as a significant obesity-associated gene expressed in the stomach (39). No other relevant evidence could be found in previous research, so this metabolic feature may be a potential novel association with BMI.

Tryptophan, an essential amino acid and endogenous compound involved in metabolic processes (11), showed the second highest significant association in the analysis. Numerous previous studies have linked tryptophan with BMI and obesity-related risk factors and diseases. For instance, a 2016 study of South African adults with HIV revealed that lower tryptophan

levels were associated with higher levels of inflammatory activity, likely caused by food insecurity (40). This underscores the potential role of SES as a mediator or effect modifier of tryptophan and obesity-related diseases. Additionally, a 2020 study reported that tryptophan, along with kynurenine, metabolic pathways were concomitantly altered in obese adults compared to non-obese controls (41). Another study in 2022 conducted global metabolomic profiling on a diverse cohort of women and found that elevated tryptophan and kynurenine levels were associated with decreased levels of microbial-derived metabolites which are critical for controlling inflammation and maintaining immune response in obese individuals (42). Altogether, these findings suggest that tryptophan is a promising metabolite to explore in the context of obesity-related diseases and that future research should consider the potential role of socioeconomic factors in mediating or modifying its effects.

Phenylalanine, a precursor for various neurotransmitters and an amino acid involved in protein synthesis (11), was the third most significant result (p -value = 0.004) in the analysis. This metabolite was identified as having a significant and relevant metabolic pathway between two groups: metabolic healthy obesity (i.e., obese but without hyperglycemia, hypertension and dyslipidemia) and metabolic abnormal obesity (i.e., obese with one or more abnormal metabolic index) (21). Additionally, phenylalanine has been found at higher levels in obese populations and those with metabolic dysfunction (e.g., insulin resistance, T2D, and high blood pressure) in general populations (26). With a significant association with BMI in our sample, phenylalanine might be a useful marker for early detection and intervention of obesity and metabolic dysfunction, however, further studies are necessary to determine the precise association and validity of this relationship.

The specific metabolites identified in this study may be potential biomarkers, etiological pathways, or therapeutic targets of BMI-related outcomes (e.g., obesity) among PWH. Although further research is required to establish a concrete relationship, the results of this study could be used to implement early interventions and provide better health outcomes.

SES was identified as a variable of interest to assess as a potential mediator or effect modifier of metabolic profiles and BMI due to its important effect on both metabolites and BMI. A recent multi-cohort analysis revealed a link between lower SES and unfavorable metabolic profiles (43). Meanwhile, extensive research has explored the impact of socioeconomic factors on BMI, finding significant effects at both individual and community levels, regardless of HIV status (44–46). However, the relationship between social strata and BMI may differ between high-income countries and LMICs, especially in the context of PWH residing in LMICs (45). Although ongoing research is examining these relationships more thoroughly through metabolomics, this study recommends further investigation of SES as a potential mediator or effect modifier between metabolic profiles and obesity to clarify the complex relationship.

Public Health Implications

The association between tryptophan and phenylalanine with BMI and obesity-related diseases may have significant public health implications. As far back as 1988, a study found evidence that altered plasma levels of these two amino acids and their response to carbohydrate intake may play a role in the regulation of food intake in obese individuals (47). Obesity is a major risk factor for a range of chronic diseases, including T2D, CVD, and some cancers (1,2,42). Identifying metabolites that are associated with BMI and obesity could help in the development of targeted interventions to prevent and manage obesity and these related diseases.

Furthermore, the potential mediating effect of SES on the relationship between metabolites and BMI highlights the need to consider social determinants of health in addressing obesity-related health disparities. Food insecurity, for example, can affect the levels of tryptophan and other metabolites that are associated with BMI, as shown in the 2016 study of South African adults with HIV (40) mentioned previously. Improving access to healthy food and addressing other social determinants of health may be essential to reducing the burden of obesity-related diseases, particularly among disadvantaged, underrepresented, and vulnerable populations.

In summary, the findings of this study may contribute to our understanding of the metabolic pathways that are associated with BMI and obesity-related diseases. Further research is necessary to confirm and extend these findings and to explore potential interventions to prevent and manage obesity and obesity-related diseases.

Limitations

The study was limited by a small sample size and inclusion of participants from a single hospital setting. Additionally, race and ethnicity can be important to consider more in depth in the model, but given that 95% of our participants identified as Black, our model was limited in its ability to further investigate the role of race in the associations.

CONCLUSION

In conclusion, this study investigated the association between 154 metabolites and BMI among PWH in South Africa. The results identified 20 unique metabolites with a significant association with BMI. Three metabolites of particular interest were 1-naphthylamine, tryptophan,

and phenylalanine, with tryptophan and phenylalanine having *a priori* associations with BMI and obesity-related diseases. The association between tryptophan and phenylalanine with BMI and obesity-related diseases may have significant public health implications as obesity is a major risk factor for a range of chronic diseases. The study also highlights the need to consider social determinants of health, such as food insecurity and SES, in addressing obesity-related health disparities. Further research is required to establish a concrete relationship and determine the precise association and validity of these metabolites with obesity-related outcomes.

REFERENCES

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. *Lancet*. 2013;382(9903):1525–1533.
2. Gallant J, Hsue PY, Shreay S, et al. Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis. *J Infect Dis*. 2017;216(12):1525–1533.
3. Boachie MK, Thsehla E, Immurana M, et al. Estimating the healthcare cost of overweight and obesity in South Africa. *Global Health Action*. 2022;15(1):2045092.
4. WHO. World Obesity Day 2022 – Accelerating action to stop obesity. 2022;(https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity). (Accessed March 8, 2023)
5. Huang J, Huffman JE, Huang Y, et al. Genomics and phenomics of body mass index reveals a complex disease network. *Nat Commun*. 2022;13(1):7973.
6. Ding Y, Lin H, Liu X, et al. Higher Prevalence of Frailty Among a Sample of HIV-Infected Middle-aged and Older Chinese Adults Is Associated With Neurocognitive Impairment and Depressive Symptoms. *The Journal of Infectious Diseases*. 2017;215(5):687–692.
7. Osegbe ID, Soriyan OO, Ogbenna AA, et al. Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. *Pan Afr Med J*. 2016;23:206.
8. South Africa NDoH, ICF. South Africa Demographic and Health Survey 2016. 2019;(https://dhsprogram.com/publications/publication-fr337-dhs-final-reports.cfm). (Accessed March 8, 2023)
9. Simbayi L, Zuma K, Zungu N, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-90 targets. 2019;(https://repository.hsrc.ac.za/handle/20.500.11910/15052). (Accessed March 8, 2023)
10. Chadeau-Hyam M, Ebbels TMD, Brown IJ, et al. Metabolic Profiling And The Metabolome-Wide Association Study: Significance Level For Biomarker Identification. *J Proteome Res*. 2010;9(9):4620–4627.
11. Slonczewski J, Foster JW. *Microbiology: An Evolving Science*. Fourth edition. New York: W.W. Norton & Company; 2017 1174 p.
12. Hanhineva K, Barri T, Kolehmainen M, et al. Comparative Nontargeted Profiling of Metabolic Changes in Tissues and Biofluids in High-Fat Diet-Fed Ossabaw Pig. *J. Proteome Res*. 2013;12(9):3980–3992.

13. Alonso A, Marsal S, Julià A. Analytical Methods in Untargeted Metabolomics: State of the Art in 2015. *Frontiers in Bioengineering and Biotechnology* [electronic article]. 2015;3. (<https://www.frontiersin.org/articles/10.3389/fbioe.2015.00023>). (Accessed April 14, 2023)
14. Szymańska E, Bouwman J, Strassburg K, et al. Gender-Dependent Associations of Metabolite Profiles and Body Fat Distribution in a Healthy Population with Central Obesity: Towards Metabolomics Diagnostics. <https://home.liebertpub.com/omi>. 2012;(https://www.liebertpub.com/doi/10.1089/omi.2012.0062). (Accessed April 14, 2023)
15. Kim MJ, Yang HJ, Kim JH, et al. Obesity-Related Metabolomic Analysis of Human Subjects in Black Soybean Peptide Intervention Study by Ultrapformance Liquid Chromatography and Quadrupole-Time-of-Flight Mass Spectrometry. *J Obes*. 2013;2013:874981.
16. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. *Nature*. 2013;500(7464):585–588.
17. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500(7464):541–546.
18. Wang Y, Liu D, Li Y, et al. Metabolomic analysis of serum from obese adults with hyperlipemia by UHPLC-Q-TOF MS/MS. *Biomed Chromatogr*. 2016;30(1):48–54.
19. Chashmian S, Hashemi Madani N, Nobakht Mothlagh Ghoochani BF, et al. The metabolome profiling of obese and non-obese individuals: Metabolically healthy obese and unhealthy non-obese paradox. *Iran J Basic Med Sci*. 2020;23(2):186–194.
20. Taylor JY, Huang Y, Zhao W, et al. Epigenome-wide association study of BMI in Black populations from InterGEN and GENOA. *Obesity*. 2023;31(1):243–255.
21. Chen H-H, Tseng YJ, Wang S-Y, et al. The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. *Int J Obes (Lond)*. 2015;39(8):1241–1248.
22. Liu C, Wang Z, Hui Q, et al. Crosstalk between Host Genome and Metabolome among People with HIV in South Africa. *Metabolites*. 2022;12(7):624.
23. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;384(9945):766–781.
24. IHME. GBD Compare. *Institute for Health Metrics and Evaluation*. 2019;(http://vizhub.healthdata.org/gbd-compare). (Accessed March 8, 2023)
25. Zuma K, Simbayi L, Zungu N, et al. The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey. *Int J Environ Res Public Health*. 2022;19(13):8125.
26. Libert DM, Nowacki AS, Natowicz MR. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: amino acid and acylcarnitine levels change along a spectrum of metabolic wellness. *PeerJ*. 2018;6:e5410.

27. Dorgan JF, Ryan AS, LeBlanc ES, et al. A comparison of associations of body mass index and dual-energy x-ray absorptiometry measured percentage fat and total fat with global serum metabolites in young women. *Obesity (Silver Spring)*. 2023;31(2):525–536.
28. Fanni G, Eriksson JW, Pereira MJ. Several Metabolite Families Display Inflexibility during Glucose Challenge in Patients with Type 2 Diabetes: An Untargeted Metabolomics Study. *Metabolites*. 2023;13(1):131.
29. Nelson KN, Hui Q, Rimland D, et al. Identification of HIV infection-related DNA methylation sites and advanced epigenetic aging in HIV+, treatment-naïve U.S. veterans. *AIDS*. 2017;31(4):571–575.
30. Wahl S, Drong A, Lehne B, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature*. 2017;541(7635):81–86.
31. CDC. All About Adult BMI. *Centers for Disease Control and Prevention*. 2022;(https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html). (Accessed April 9, 2023)
32. Alebel A, Sibbritt D, Petrucka P, et al. Association Between Body Mass Index Variation and Early Mortality Among 834 Ethiopian Adults Living with HIV on ART: A Joint Modelling Approach. *Infect Dis Ther*. 2023;12(1):227–244.
33. Taylor AE, Richmond RC, Palviainen T, et al. The effect of body mass index on smoking behaviour and nicotine metabolism: a Mendelian randomization study. *Hum Mol Genet*. 2019;28(8):1322–1330.
34. Wahi G, Anand SS. Race/Ethnicity, Obesity, and Related Cardio-Metabolic Risk Factors: A Life-Course Perspective. *Curr Cardiovasc Risk Rep*. 2013;7(5):326–335.
35. Mullings L, Torres JB, Fuentes A, et al. The Biology of Racism. *American Anthropologist*. 2021;123(3):671–680.
36. Noble WS. How does multiple testing correction work? *Nat Biotechnol*. 2009;27(12):1135–1137.
37. Kumar N, Hoque MdA, Sugimoto M. Robust volcano plot: identification of differential metabolites in the presence of outliers. *BMC Bioinformatics*. 2018;19(1):128.
38. PubChem. 1-Naphthylamine. (https://pubchem.ncbi.nlm.nih.gov/compound/8640). (Accessed April 16, 2023)
39. Chen J, Chen L, Sanseau P, et al. Significant obesity-associated gene expression changes occur in the stomach but not intestines in obese mice. *Physiol Rep*. 2016;4(10):e12793.
40. Bipath P, Levay PF, Viljoen M. Tryptophan depletion in context of the inflammatory and general nutritional status of a low-income South African HIV-infected population. *Journal of Health, Population and Nutrition*. 2016;35(1):5.

41. Cussotto S, Delgado I, Anesi A, et al. Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated With Systemic Inflammation. *Front Immunol.* 2020;11:557.
42. Smith A, Gu Q, Amos-Abanyie EK, et al. Tryptophan metabolism is associated with obesity and triple negative breast cancer risk in black and white women. *Cancer Research.* 2022;82(12_Supplement):3022.
43. Robinson O, Carter AR, Ala-Korpela M, et al. Metabolic profiles of socio-economic position: a multi-cohort analysis. *Int J Epidemiol.* 2020;50(3):768–782.
44. Anekwe CV, Jarrell AR, Townsend MJ, et al. Socioeconomics of Obesity. *Curr Obes Rep.* 2020;9(3):272–279.
45. Dinsa G, Goryakin Y, Fumagalli E, et al. Obesity and socioeconomic status in developing countries: a systematic review. *Obes Rev.* 2012;13(11):1067–1079.
46. Nagata JM, Fiorella KJ, Young SL, et al. Socio-demographic and health associations with body mass index at the time of enrollment in HIV care in Nyanza Province, Kenya. *AIDS Care.* 2013;25(12):10.1080/09540121.2013.775399.
47. Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: Response to carbohydrate intake and tryptophan supplements. *Metabolism.* 1988;37(7):672–676.